|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for TEAD2 |
 Gene summary |
| Basic gene Info. | Gene symbol | TEAD2 |
| Gene name | TEA domain family member 2 | |
| Synonyms | ETF|TEAD-2|TEF-4|TEF4 | |
| Cytomap | UCSC genome browser: 19q13.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001256658.1, NM_001256659.1,NM_001256660.1,NM_001256661.1,NM_001256662.1, NM_003598.1, | |
| Description | transcriptional enhancer factor TEF-4 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 601729 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000074219 | ||
| Vega : OTTHUMG00000183174 | ||
| Protein | UniProt: Q15562 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_TEAD2 | |
| BioGPS: 8463 | ||
| Pathway | NCI Pathway Interaction Database: TEAD2 | |
| KEGG: TEAD2 | ||
| REACTOME: TEAD2 | ||
| Pathway Commons: TEAD2 | ||
| Context | iHOP: TEAD2 | |
| ligand binding site mutation search in PubMed: TEAD2 | ||
| UCL Cancer Institute: TEAD2 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0035329 | hippo signaling | 18579750 |
| Top |
| Ligand binding site mutations for TEAD2 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | F233 | V231I | BLCA | 1 | K301 | L299P | COAD | 1 | K301,W303 | F302L | COAD | 1 | L383 | N385Y | LUAD | 1 | V355 | Q353H | LUSC | 1 | W303 | D305V | OV | 1 | V347 | S349F | SKCM | 1 | K277 | D276N | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for TEAD2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | L383 | N385Y | 0.11844568 | K277 | D276N | -1.6017095 | K301 | L299P | -1.2459281 | K301 | F302L | -1.0796337 | W303 | F302L | -1.0796337 | W303 | D305V | -0.83136035 | F233 | V231I | -0.77676866 | V355 | Q353H | -0.54529183 | V347 | S349F | -0.54493496 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for TEAD2 from PDB |
| Top |
| Differential gene expression and gene-gene network for TEAD2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for TEAD2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0032460 | Polycystic Ovary Syndrome | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for TEAD2 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of TEAD2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | 5E4 | 2-[(3-BROMOPHENYL)AMINO]BENZOIC ACID | 5dqe | A | F233 V347 L383 | 5E4 | 2-[(3-BROMOPHENYL)AMINO]BENZOIC ACID | 5dqe | B | F233 V347 L383 | FLF | FLUFENAMIC ACID | 5dq8 | A | F233 V347 V355 L383 | FLF | FLUFENAMIC ACID | 5dq8 | B | F233 V347 V355 L383 | FLF | FLUFENAMIC ACID | 5dq8 | B | K277 K301 W303 | 5E4 | 2-[(3-BROMOPHENYL)AMINO]BENZOIC ACID | 5dqe | B | K277 K301 W303 |
| Top |
| Conservation information for LBS of TEAD2 |
| Multiple alignments for Q15562 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |